Complete Story
10/13/2025
Recent Oncology Related FDA Approvals and Expanded Indications
FDA Approves Regeneron's Libtayo® (cemiplimab-rwlc) for Adjuvant Treatment of Adults with Cutaneous Squamous Cell Carcinoma (CSCC)
FDA Approves Jazz Pharmaceutical's Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer in Adults
FDA Approves Lilly's Inluriyo (imlunestrant) for the Treatment of Adults With ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
More InfoReport Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
